SEC Comment Letter 0000000000-23-009984 to Can-Fite BioPharma Ltd. (CANF)
Can-Fite BioPharma Ltd.
Date: Sept. 8, 2023 · CIK: 0001536196 · Accession: 0000000000-23-009984
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274316
Letter
United States securities and exchange commission logo September 8, 2023 Motti Farbstein Chief Financial Officer Can-Fite BioPharma Ltd. 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petach-Tikva 4951778, Israel Re:Can-Fite BioPharma Ltd. Registration Statement on Form F-3 Filed September 1, 2023 File No. 333-274316 Dear Motti Farbstein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7439 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gary Emmanuel
Show Raw Text
United States securities and exchange commission logo
September 8, 2023
Motti Farbstein
Chief Financial Officer
Can-Fite BioPharma Ltd.
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
Re:Can-Fite BioPharma Ltd.
Registration Statement on Form F-3
Filed September 1, 2023
File No. 333-274316
Dear Motti Farbstein:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7439 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Gary Emmanuel